Paingone pens are Class IIa Medical Devices and offer an effective form of pain relief for varying levels of pain – including chronic, and without the use of drug therapy. Used throughout the NHS and in professional practices the efficacy of the device is well proven. This latest a double-blind, placebo-controlled 8-month study by Hospital General Universitario Morales Meseguer draws some interesting and powerful conclusions.
The efficacy of the handheld TENS pen, used on demand for 28 days, has been evaluated both for the relief of general musculoskeletal origin pain as well as for acute and chronic pain of the same origin in particular;
The following conclusions were drawn from the data evaluation and analysis of this study:
- Paingone pen is effective in relieving chronic musculoskeletal pain
- The use of Paingone pen is safe and well tolerated
- Paingone pen reduces the use of medication for patients with acute pain
- 83% of individuals with chronic pain who used Paingone pen felt that their pain had gone from severe to moderate and in some cases to no pain at all
- Paingone pen improves the quality of life of subjects
As part of Tower Health’s on-going post marketing surveillance activities for its medical device Paingone pen, an end-user survey was conducted during March and April 2017. The conclusions for the survey can be found below, alternativly view the complete report here.
Application frequency per day
4 in 5 users find that one or two applications per day are sufficient.
Distribution of Percived Effectivness of Using Paingone Pen
More than 9 in 10 respondents find Paingone to be effective to some degree for their condition. 1 in 4 finds Paingone to be “very effective”.